Dr. Igor Chaplik, DO
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 602
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license OS9145
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Aesthetix Skin and Surgery Center (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 602
- Services billed
- 7,076
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 3,310 | 333 |
| Established patient office or other outpatient visit, 20-29 minutes | 967 | 454 |
| Destruction of precancer skin growth, 1 growth | 764 | 387 |
| Biopsy of related skin growth, first growth | 465 | 303 |
| Established patient office or other outpatient visit, 10-19 minutes | 262 | 176 |
| Biopsy of related skin growth, each additional growth | 183 | 112 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 139 | 100 |
| New patient office or other outpatient visit, 30-44 minutes | 138 | 138 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 105 | 29 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 89 | 59 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Ft Lauderdale, FL | 306 |
| Clobetasol Propionate Other prescribers in Ft Lauderdale, FL | 281 |
| Doxycycline Hyclate Other prescribers in Ft Lauderdale, FL | 174 |
| Ciclopirox (ciclopirox olamine) | 99 |
| Fluorouracil Other prescribers in Ft Lauderdale, FL | 74 |
| Ketoconazole Other prescribers in Ft Lauderdale, FL | 62 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Ft Lauderdale, FL | 57 |
| Clindamycin Phosphate Other prescribers in Ft Lauderdale, FL | 53 |
| Hydrocortisone Other prescribers in Ft Lauderdale, FL | 35 |
| Fluconazole Other prescribers in Ft Lauderdale, FL | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 102 payments worth $2,235 in total to this clinician.
| AbbVie Inc. | $453 |
|---|---|
| Janssen Biotech, Inc. | $399 |
| UCB, Inc. | $185 |
| Incyte Corporation | $171 |
| Revance Therapeutics, Inc. | $164 |
| Novartis Pharmaceuticals Corporation | $136 |
| Regeneron Healthcare Solutions, Inc. | $92.39 |
| Organon LLC | $85.61 |
| Food and Beverage | $2,235 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $1,153,212 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
Pfizer Inc. - TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN‑A MICRO® Gel Microsphere 0.04% in the Treatment of Acne Vulgaris
Sun Pharmaceutical Industries Inc. - Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
Teva Pharmaceuticals USA, Inc. - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 52 weeks of treatment
Takeda Pharmaceuticals U.S.A., Inc. - TPNC-2412
Sun Pharmaceutical Industries Inc. - A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
Sanofi US Services Inc. · Completed · NCT06073119 - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.